Torrey Coast Foundation

The Torrey Coast Foundation channels all of its grantmaking through GEMINI (Gastroesophageal Malignancies Investigator Network Initiative), a research consortium operating at teamgemini.org and led scientifically by Dr. Sandra Ryeom. This structure has profound implications for applicants: the foundation is not a traditional open-call grantmaker. Its internal record is marked "preselected only," meaning it identifies researchers through its established consortium network rather than advertising standing RFPs.

The GEMINI model functions as a research ecosystem rather than a grant program. The foundation's philanthropic priority is singular — preclinical research and Phase 1 clinical trials targeting gastric and esophageal cancers — and every dollar flows through multi-institutional collaborations connecting scientists and oncologists at elite academic medical centers. Top grantees include Columbia University ($2.7M across 5 grants), UC San Diego Foundation ($2.57M across 2 grants), Memorial Sloan-Kettering Cancer Center ($793K), the Broad Institute ($1.03M), and Cornell University-Weill Medical College ($1.15M). These institutions form the inner core of the network.

For first-time applicants, two viable pathways exist. The first and most direct is through the GEMINI consortium itself: reach out via teamgemini.org to express scientific interest, demonstrate alignment with gastroesophageal cancer research, and ideally arrive with an introduction from an existing GEMINI grantee. The foundation explicitly states it processes funding requests "within days rather than months" — a deliberate departure from slow NIH and NCI grant cycles. This speed signals that GEMINI moves on compelling science quickly; proposals must therefore be tight and decision-ready upon submission.

The second pathway is through competitive institutional programs that Torrey Coast co-sponsors with established research organizations. The AACR-Torrey Coast Foundation Transpacific Gastric and Esophageal Cancer Research Partnership Grant represents an open-competition route administered by the American Association for Cancer Research. This pathway requires AACR Active membership and at least one co-PI based in Asia.

In either pathway, relationship cultivation with existing GEMINI investigators at Columbia, UCSD, Sloan-Kettering, or the Broad Institute is the most reliable entrée. The DeGregorio Family Foundation, which has received $1.19M in Torrey Coast co-funding, also serves as an indirect pathway — its network frequently surfaces researchers for GEMINI collaboration.

Torrey Coast Foundation has made 51 recorded grants totaling $19,763,051, with an average award of $387,511. The typical direct grant size based on recent years ranges from $125,000 to $535,000, with a median of $253,334. These figures mask significant variance driven by a handful of large institutional awards: $5.55M to the Entertainment Industry Foundation (Stand Up 2 Cancer) across 3 grants, and $2.7M to Columbia University across 5 grants rank as the two largest recipient relationships. At the low end, $25,000 grants have gone to Médecins Sans Frontières and the International Committee of the Red Cross — the only grants outside the core cancer research mandate.

Annual giving has fluctuated dramatically as the foundation scaled. In 2020, $2.88M was distributed from $120,880 in assets. In 2021, $1.17M from $5M in assets. The foundation transformed in fiscal 2022, when $305M in new contributions vaulted assets to $303M and drove $11.7M in total giving. In fiscal 2023 (the most recent complete filing), grants_paid totaled $4.38M against total giving of $5.7M, with $10.85M in net investment income suggesting the portfolio is now largely self-sustaining. Total assets reached $317M in fiscal 2024 on $15M in total revenue.

Geographically, New York institutions dominate (15 grants), followed by California (10 grants, reflecting the San Diego base), Massachusetts (7 grants), Pennsylvania (3), Texas (3), Maryland (3), Ohio (2), Georgia (2), and Utah (2). This maps closely to the concentration of elite cancer research programs: Memorial Sloan-Kettering and Columbia in New York; UCSD and La Jolla Institute in California; Harvard/MGH and Dana-Farber in Massachusetts; MD Anderson in Texas.

By program area, approximately 95% of grantmaking targets gastroesophageal cancer research. Within that universe, roughly 60% supports immunotherapy approaches (T-cell targeting, myeloid cell modulation, PD-1/PD-L1 combinations), 25% funds translational platforms (organoids, PRISM screening, genetically engineered mouse models), and 15% supports collaborative infrastructure and network grants. Grants consistently fund specific investigator-driven projects rather than general operating support.

The database peers for Torrey Coast Foundation are matched by asset size (~$312–322M) and NTEE category (T — Philanthropy & Grantmaking), not programmatic focus. None are cancer research foundations. This reflects the unusually specialized nature of Torrey Coast — among foundations at this asset level, one devoted entirely to a single cancer indication is rare.

Within cancer philanthropy, more meaningful comparisons are the DeGregorio Family Foundation (direct Torrey Coast co-funder), the Mark Foundation for Cancer Research (ASPIRE co-funder), and Stand Up 2 Cancer/Entertainment Industry Foundation (receives $5.55M from Torrey Coast). All three share the upper GI cancer focus but operate with broader disease scope and significantly higher public profiles. Torrey Coast distinguishes itself through hyper-specialized focus on one cancer type, rapid decision-making (days vs. months), no standing application deadlines, and a consortium operating model — no comparable foundation at this asset level concentrates 95%+ of giving on a single cancer indication while maintaining the agility of a small research program.

The most significant recent development is the launch of the AACR-Torrey Coast Foundation Transpacific Gastric and Esophageal Cancer Research Partnership Grant, a new competitive program administered through the American Association for Cancer Research. Guidelines were released in November 2025, with a January 15, 2026 application deadline, award decisions expected April 2026, and grant terms beginning July 1, 2026. The $400,000 two-year award marks Torrey Coast's first open-competition grant with an explicitly international scope, requiring collaboration between a US institution and an Asian institution. This signals a strategic decision to leverage Asia's high gastric cancer incidence and growing translational research capacity.

In March 2025, the DeGregorio Family Foundation — the closest co-funding partner — announced a $1M award to researchers at Dana-Farber Cancer Institute and Massachusetts General Hospital for immunotherapy improvement in gastroesophageal cancer, with Torrey Coast contributing $450,000 of that total. The Mark Foundation for Cancer Research also ran its ASPIRE award program for upper GI tract cancers as a joint commitment with both the DeGregorio Foundation and Torrey Coast, underscoring the syndicated co-funding model.

On the financial side, fiscal 2024 data shows $317M in total assets and $15M in total revenue — growing investment returns that could support increased grantmaking above the $5.7M distributed in 2023. Alan Braynin continues as President with $0 personal compensation, and Dr. Sandra Ryeom leads scientific direction through the GEMINI consortium. No leadership transitions have been publicly announced.

The most critical thing to understand about applying to Torrey Coast Foundation is that the standard cold-application model does not apply here. The foundation is "preselected only" — meaning it identifies researchers through the GEMINI network rather than maintaining a public RFP calendar. That said, three specific actions can move a researcher from unknown to fundable.

Enter the GEMINI network directly. Visit teamgemini.org and submit a brief research description through the contact form. The foundation explicitly welcomes new investigators, especially those with expertise in adjacent fields (immunology, structural biology, computational oncology, bioengineering) who want to apply their skills to gastric or esophageal cancer. A network inquiry is not the same as a grant application — expressing interest and demonstrating scientific credibility is the correct first step.

Build relationships with existing GEMINI grantees. Researchers at Columbia University, UC San Diego, Memorial Sloan-Kettering, the Broad Institute, or Massachusetts General Hospital are the natural connectors. A co-investigator from one of these institutions increases the likelihood of a funded proposal substantially, as GEMINI consistently favors multi-institutional, collaborative grants — every top grantee in the portfolio has been funded multiple times through multi-site teams.

Keep proposals exceptionally focused. The standard format is a two-page proposal (background, proposed experiments, rationale, expected outcomes, timeline) plus biosketch and justified budget. Do not submit an NIH-style application. The median grant is $253,334 and the emphasis is on "high-risk, high-reward" research that "may not be able to get funding from other sources" — GEMINI is looking for bold, creative ideas that haven't yet earned institutional validation.

In the proposal, use language that reflects the foundation's ecosystem philosophy: "translational pathway," "preclinical-to-Phase I bridge," "collaborative multi-site investigation," and "novel target in gastroesophageal malignancy." Always articulate the clinical relevance — proposals framed as pure bench science without a patient impact endpoint are not a fit.

Timing is flexible: there are no standing submission deadlines for direct GEMINI grants. Submit when the science is strong, not when a calendar deadline forces it.